Open Access

CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone

  • Authors:
    • Mingxiao Wen
    • Xiaoqing Dou
    • Shuzhen Zhang
    • Bin Wang
    • Jiangyan Xu
    • Wenchao Zhang
    • Feifei Wang
  • View Affiliations

  • Published online on: June 1, 2022     https://doi.org/10.3892/mmr.2022.12761
  • Article Number: 245
  • Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies and primarily presents with hyperandrogenism. Although environmental factors and genetic factors are thought to be the major reason, there still exists a lot of questions need to be answered. High expression of C‑terminal‑binding protein 1 antisense (CTBP1‑AS) was identified as an independent risk factor for PCOS; however, the molecular mechanism of CTBP1‑AS in PCOS regulation is unknown. In the present study, the expression level of CTBP1‑AS was found to be significantly upregulated in patients with PCOS compared with healthy control patients. CTBP1‑AS knockdown was demonstrated to reduce the proliferation and promote the apoptosis of granulosa tumor cells in vitro. It was also identified that the two core catalytic subunits of Polycomb repressive complex 2 (enhancer of zeste homolog 2 and embryonic and ectoderm development protein) interacted with CTBP1‑AS in primary granulosa cells and KGN cells. In addition, cryptotanshinone treatment was demonstrated to effectively downregulate CTBP1‑AS expression level. Data from the present study suggested a pathophysiological role of CTBP1‑AS in PCOS and may provide a new potential target for PCOS treatment.
View Figures
View References

Related Articles

Journal Cover

July-2022
Volume 26 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wen M, Dou X, Zhang S, Wang B, Xu J, Zhang W and Wang F: CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone. Mol Med Rep 26: 245, 2022.
APA
Wen, M., Dou, X., Zhang, S., Wang, B., Xu, J., Zhang, W., & Wang, F. (2022). CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone. Molecular Medicine Reports, 26, 245. https://doi.org/10.3892/mmr.2022.12761
MLA
Wen, M., Dou, X., Zhang, S., Wang, B., Xu, J., Zhang, W., Wang, F."CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone". Molecular Medicine Reports 26.1 (2022): 245.
Chicago
Wen, M., Dou, X., Zhang, S., Wang, B., Xu, J., Zhang, W., Wang, F."CTBP1‑AS upregulation is associated with polycystic ovary syndrome and can be effectively downregulated by cryptotanshinone". Molecular Medicine Reports 26, no. 1 (2022): 245. https://doi.org/10.3892/mmr.2022.12761